£10 m program to fast-track cardiometabolic innovation from lab to NHS

UK-first £10 million UKRI-backed program will take new therapeutics, medical devices and digital health tools for heart disease, diabetes and obesity, from development through real-world validation to adoption in the NHS, private healthcare and international markets.

A new London program will support cardiometabolic innovation at every stage of its journey, from early development to adoption and scale-up in the UK and internationally, helping patients across London benefit more quickly from new ways to prevent, detect and treat heart disease, diabetes and obesity.

The Frontier Innovation for Cardiometabolic Disease Programme, backed by £10 million from UK Research and Innovation's Local Innovation Partnerships Fund, supported by the Mayor of London, brings together partners across London to accelerate the development, validation and adoption of innovations for heart disease, diabetes and obesity.

This initiative comprises two complementary £5 million programs: Venture Builder and Validate and Scale.

The Venture Builder program will support the creation and growth of new ventures developing therapeutics, through BioInnovation Institute, one of Europe’s leading innovation institutes backed by Novo Nordisk Foundation, and medical technologies, through King’s College London’s London Institute for Healthcare Engineering, with King’s Health Partners also contributing to the wider program.

The Validate and Scale program is a partnership between private healthcare providers and the NHS, that will enable companies to test new solutions to priority cardiometabolic challenges in real clinical settings, including the Harley Street Health District, generating evidence to support adoption in the NHS, reaching patients across London.

UCLPartners is leading this work collaboration with Harley Street Health District, Imperial College Health Partners and Health Innovation Network South London. The London Health Innovation networks are helping connect proven innovations with NHS systems.

In the UK, some promising health technologies never reach patients. They often stall because companies can struggle to gather the evidence the NHS and other healthcare providers need to adopt them. This initiative gives those companies a faster route to that evidence.

Together, London’s three health innovation networks will then help spread proven innovations across NHS services, so that patients across the capital and beyond can benefit more quickly.

Priorities for the program span the full cardiometabolic prevention pathway, from earlier identification of risk to interventions that reduce risk, support healthier lifestyles and improve ongoing management of conditions such as high blood pressure, atrial fibrillation and high cholesterol. The program will prioritise innovations that can reduce inequalities in cardiometabolic outcomes, with evidence generated across London’s diverse populations.

Across the program, partners aim to leverage up to £300 million in private investment and create up to 1,000 high-value jobs in London.

The Venture Builder program expects to support more than 30 ventures, start four to six clinical trials and attract £200 million of private investment.

The Validate and Scale project aims to engage more than 100 companies, give tailored support to at least 20 and help at least five breakout-stage companies validate and scale in London, leveraging £50 million to £100 million of private investment.

Howard Dawber, Deputy Mayor of London for Business and Growth, said: “London is home to some of the world's leading hospitals, researchers and innovators, and we're proud to support this program to tackle major health challenges including heart disease, diabetes and obesity.

“This collaboration can help pioneer new technologies and treatments, potentially saving lives and improving care for thousands of Londoners, while strengthening our world-leading life sciences sector.”

Professor Kevin Fenton CBE, Regional Director of Public Health, NHS England London, said: “Cardiovascular disease (CVD) causes one in four deaths in London, with the greatest burden falling on our most deprived communities and those experiencing health inequalities. Yet much of this burden is preventable. Hundreds of thousands of Londoners are living with undiagnosed high blood pressure, putting them at unnecessary risk of heart attacks and strokes.

“We know that earlier detection and effective treatment save lives, but we must find new ways to reach people who are too often missed by traditional services. Through our London Million Hearts and Minds CVD Prevention program, we are bringing together the NHS, local government, communities and industry to accelerate prevention at scale.

“This innovative partnership harnesses the expertise, technology and reach of the independent sector to tackle one of London's greatest public health challenges. It is a powerful example of how working differently, across traditional boundaries, can help us detect risk earlier, prevent avoidable illness and build a healthier, more equitable London.”

Mark Kildea, Chief Executive of Harley Street Health District, said: “Forty percent of London’s independent healthcare happens in Harley Street Health District, and we have one of the greatest concentrations of clinical expertise anywhere in the world. Many of the world-leading consultants who practise here also work in the NHS. That gives us a real opportunity to put the independent sector to work on one of London’s most pressing health challenges.

“Through this program, companies will be able to test their ideas with real patients and build the evidence to support adoption in the NHS, grow within private healthcare and expand into international markets. Most importantly, it will help good ideas reach patients sooner.”

This partnership is about drawing on London’s world leading assets to bring the most effective innovations to the NHS, so patients across the city can benefit faster from new technologies. By harnessing the agility of private hospitals to test innovations quickly, and the scale of the NHS to adopt what works, we can ensure the best care is available to patients with cardiovascular disease, improving outcomes and experiences for the thousands of people living with this disease”

Dr Chris Laing, Chief Executive Officer, UCLPartners

Dr Dominique Allwood MBE, Chief Executive Officer of Imperial College Health Partners, said: “Cardio-renal-metabolic health is one of our three strategic missions for research and innovation in North West London, reflecting both the scale of the challenge and the opportunity to transform outcomes for patients and communities through innovation. This exciting program builds on that ambition, providing a vital bridge between promising innovation, real-world evidence and implementation in clinical practice. By combining London's world-leading research and innovation strengths with the needs of our diverse populations, we have a real opportunity to accelerate the adoption of solutions that improve prevention, tackle health inequalities and deliver better outcomes for patients.”

Dr Rishi Das-Gupta, Chief Executive Officer of the Health Innovation Network South London said: “CVD is the largest avoidable causes of death and requires behavior change to improve. We are excited about working on this program using our long history of working with the private healthcare providers which acts as a good test environment for change programs that can be used and rolled out across the NHS to make an impactful difference.”

Louise Clemmensen, Director of BioInnovation Institute, said: “We are delighted to bring BioInnovation Institute’s innovation platform to the UK to help address the longstanding innovation gap in cardiometabolic disease, where limited early-stage capital and support have held back promising startups. With the support of the Novo Nordisk Foundation and LIPF funding, we can help more entrepreneurs turn breakthrough science into innovative solutions that benefit patients.”

Professor Sebastien Ourselin FREng FMedSci, Assistant Principal (Innovation) and Director, London Institute for Healthcare Engineering, King’s College London, said: "By combining the expertise of the London Institute for Healthcare Engineering in translating healthcare technologies with the BioInnovation Institute’s outstanding track record in venture creation, we can help innovators turn promising discoveries into companies, attract new investment into London and accelerate the development of solutions for patients living with cardiometabolic disease. It's an exciting opportunity to deliver both health and economic benefits at scale." 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Could ultraprocessed foods affect your brain before you notice?